0.37% 0.1298

Tema Etf Trust Tema Obesity Cardiometabolic Etf (HRTS)

Schlusskurs vom Vortag:

24-Stunden-Volumen:

Relative Volume:

Marktkapitalisierung:

Nettoeinkommen (Verlust:

Netto-Cashflow:

1W Leistung:

1M Leistung:

6M Leistung:

1J Leistung:

1-Tages-Spanne:

1-Wochen-Bereich:

52-Wochen-Spanne:

Tema Etf Trust Tema Obesity Cardiometabolic Etf Stock (HRTS) Company Profile

Tema Etf Trust Tema Obesity Cardiometabolic Etf

Nächster Verdiensttermin

Neueste SEC-Einreichungen

HRTS's Discussions on Twitter

Tema Etf Trust Tema Obesity Cardiometabolic Etf Aktie (HRTS) Neueste Nachrichten

Finanzdaten der Tema Etf Trust Tema Obesity Cardiometabolic Etf-Aktie (HRTS)

Es liegen keine Finanzdaten für Tema Etf Trust Tema Obesity Cardiometabolic Etf (HRTS) vor. Überprüfen Sie andere Aktien für weitere Informationen.

Tema Etf Trust Tema Obesity Cardiometabolic Etf (HRTS)

Tema Etf Trust Tema Obesity Cardiometabolic Etf Stock (HRTS) Company Profile

Tema Etf Trust Tema Obesity Cardiometabolic Etf Aktie (HRTS) Neueste Nachrichten

5 Small-cap Biotech ETFs to Watch (Updated 2024) - Investing News Network

5 Small-cap Biotech ETFs to Watch (Updated 2024) - Nasdaq

Tema Cardiovascular and Metabolics ETF (NASDAQ:HRTS) Shares Up 0.1% - Defense World

Beyond Novo and Eli Lilly: Watch these biotech and weight loss drug names, fund manager says - CNBC

HRTS: Generating Alpha In Obesity Treatment (NASDAQ:HRTS) - Seeking Alpha

ETFs in Focus as Competition Heats Up in Weight Loss Drug Segment - Yahoo Finance

HRTS: Exposure To GLP-1 Drug Developers Means Plenty Of Upside - Seeking Alpha

ETF Innovators: 11 people disrupting the industry, creating unique products, and delivering mammoth returns - Business Insider

ETF Innovators: 11 disruptive people with unique products, high return - Business Insider

EXCLUSIVE: GLP-1 Weight-Loss Drugs Could Become A Trillion-Dollar Market, Predicts Tema ETFs CEO - Benzinga

This ETF is trying to satisfy appetites for weight loss stocks - CNBC

ETF IQ: Mutual Fund Managers Have the Luxury to Just Say 'No' - Bloomberg

ETF IQ: Mutual Fund Managers Have the Luxury to Just Say ‘No’ - Bloomberg

Tema Cardiovascular and Metabolics ETF (NASDAQ:HRTS) Stock Price Down 1.1% - Defense World

Spot Ether ETF: a Crypto Game Changer? - Opto RoW

ETFs to Profit from the Weight Loss Drug Boom - Zacks Investment Research

ETFs to Profit from the Weight Loss Drug Boom - Yahoo Finance

OZEM, Weight Loss Drug ETFs: Should You Invest? - etf.com

Investing in the diabesity epidemic: a breakthrough moment - Opto RoW

Obesity Market to Reach $150B as Demand Grows, Supply Stabilizes: Reuters - BioSpace

Ethereum Surges: Spot ETFs Drive Growth For the Second Largest Cryptocurrency - The Globe and Mail

Play These New ETFs to Tap Lucrative Weight Loss Drug Market - Zacks Investment Research

Play These New ETFs to Tap Lucrative Weight Loss Drug Market - Yahoo Finance

Thematic ETF Winners of the Q1 2024 Earnings Season - ETF Trends

S&P 500: April Selloff Could Be a Very Good Thing for the Months Ahead - Investing.com India

IBD Stock Of The Day Pops After Obesity Drug Crushes Sales Views - Investor's Business Daily

The Impact of Bitcoin Halving on Investors and ETFs to Explore - The Globe and Mail

A New Horizon: Horizons ETF Management Canada to rebrand as Global X - The Globe and Mail

Webcast: How to Invest in the Weight Loss Drug Revolution - ETF Trends

This weight-loss ETF has performed well. Here’s a look at other options. - MarketWatch

Healthcare ETFs for the Weight-Loss Drug Boom & Beyond - Zacks Investment Research

Healthcare ETFs for the Weight-Loss Drug Boom & Beyond - Yahoo Finance

Is the global battle against obesity an opportunity for investors? - InvestmentNews

First Weight Loss ETF from Tema ETFs Announces Name Change, Tops $50 Million AUM - Markets Insider

Feisty Rivals Take On Eli Lilly, Novo Nordisk On Weight Loss - Investor's Business Daily

'Continued innovation' is key when investing in weight loss trend - Yahoo Finance

Weight-Loss Drugs: How Outliers Like Biohaven, Regeneron Are Taking On The Muscle Dilemma In The Obesity Space - Investor's Business Daily

The Truth HRTSETF Focus on TheStreet: ETF research and Trade Ideas - TheStreet

US ETF launches from 16th to 23rd November, 2023 - ETF Express

New ETF invested in Ozempic maker and exposed to other obesity drugs falls in first day of trade - MarketWatch

New ETF Tracks Developers of Obesity Drugs Amid Ozempic Hype - BNN Bloomberg

New ETF Tracks Developers of Obesity Drugs Amid Ozempic Hype - Wealth Management

Finanzdaten der Tema Etf Trust Tema Obesity Cardiometabolic Etf-Aktie (HRTS)

Umsatz

Nettogewinn

Free Cashflow

ENV

Ähnlich wie HRTS